Secukinumab for Long-Term Treatment of Psoriatic Arthritis: A Two-Year Followup From a Phase III, Randomized, Double-Blind Placebo-Controlled Study-Reference-Cited by-同舟云学术

Secukinumab for Long-Term Treatment of Psoriatic Arthritis: A Two-Year Followup From a Phase III, Randomized, Double-Blind Placebo-Controlled Study

Published:2017-02-25 Issue:3 Volume:69 Page:347-355
ISSN:2151-464X
Container-title:Arthritis Care & Research
language:en
Short-container-title:Arthritis Care & Research

Author:

Kavanaugh Arthur¹,Mease Philip J.²,Reimold Andreas M.³,Tahir Hasan⁴,Rech Jürgen⁵,Hall Stephen⁶,Geusens Piet⁷,Wang Zailong⁸,Pricop Luminita⁸,Mpofu Shephard⁸,

Affiliation:

1. University of California at San Diego; La Jolla California

2. Swedish Medical Center and University of Washington School of Medicine; Seattle

3. Dallas VA Medical Center and University of Texas Southwestern Medical Center; Dallas

4. Whipps Cross University Hospital; London UK

5. Friedrich Alexander University, Erlangen-Nürnberg (FAU), Universitätsklinikum Erlangen; Germany

6. Cabrini Monash University; Victoria Australia

7. CAPHRI/NUTRIM, Maastricht University Medical Centre; Maastricht The Netherlands

8. Novartis Pharma; East Hanover New Jersey

Publisher

Wiley

Subject

Rheumatology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/acr.23111/fullpdf

Reference29 articles.

1. Guidelines of care for the management of psoriasis and psoriatic arthritis. Section 2: psoriatic arthritis. Overview and guidelines of care for treatment with an emphasis on the biologics;Gottlieb;J Am Acad Dermatol,2008

2. The 2012 BSR and BHPR guideline for the treatment of psoriatic arthritis with biologics;Coates;Rheumatology (Oxford),2013

3. European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update;Gossec;Ann Rheum Dis,2016

4. Treatment recommendations for psoriatic arthritis;Ritchlin;Ann Rheum Dis,2009

5. Secukinumab retreatment-as-needed versus fixed-interval maintenance regimen for moderate to severe plaque psoriasis: a randomized, double-blind, non-inferiority trial (SCULPTURE);Mrowietz;J Am Acad Dermatol,2015

Cited by 75 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Safety and Efficacy of Bimekizumab in Patients with Psoriatic Arthritis: 2-Year Results from Two Phase 3 Studies;Rheumatology and Therapy;2024-08-31

2. Case report: Inflammatory bowel disease triggered by secukinumab in a female case of axial spondyloarthritis accompanied with symptomatic epilepsy;International Journal of Rheumatic Diseases;2024-05

3. Effectiveness of secukinumab in patients with psoriasis and psoriatic arthritis in a Saudi real-world setting;Advances in Rheumatology;2024-04-29

4. Efficacy and Safety of Secukinumab in US Patients with Psoriatic Arthritis: A Subgroup Analysis of the Phase 3 FUTURE Studies;Rheumatology and Therapy;2024-04-16

5. Effectiveness and safety of biological and target synthetic drugs treatment for psoriatic arthritis: a systematic review with network meta-analysis;Advances in Rheumatology;2024-03-21